Literature DB >> 16109316

Antihypertensive treatment alters the predictive strength of pulse pressure and other blood pressure measures.

James Greenberg1.   

Abstract

BACKGROUND: The objective of this study was to assess whether antihypertensive treatment affects the predictive power of brachial pulse pressure.
METHODS: Data from the First National Health and Nutrition Examination Survey Epidemiologic Follow Up Study were used to conduct Cox regression analyses. There were 487 cardiovascular disease (CVD) and 348 coronary heart disease (CHD) deaths during an 8.6-year follow-up among 2939 hypertensive subjects 33 to 87 years of age. A correction was made for the regression-dilution bias.
RESULTS: Pulse pressure (PP) was a significant single predictor for treated, but not untreated, hypertensive subjects. The hazard ratio (95% confidence interval) for CVD mortality for an 10-mm Hg increment of PP was 1.16 (95% CI = 1.08 to 1.25) for treated hypertensive subjects, and 1.12 (95% CI = 0.99 to 1.26) for untreated hypertensive subjects. Also, PP was a significant predictor after accounting for the effects of mean arterial pressure (MAP), but only in treated hypertensive subjects. The pattern was opposite for diastolic pressure (DBP). Analysis of antihypertensive treatment trends suggests that clinicians focused treatment more on hypertensive subjects with elevated DBP and low PP during the 1970s and early 1980s, thereby causing DBP to become a weak predictor and PP a strong predictor among treated hypertensive subjects. This tendency was particularly noticeable at higher ages. For instance, among hypertensive subjects > or =65 years of age during this period, the percentage who were treated increased from 7.6% to 45.0%, and the ratio of subjects with isolated systolic hypertension to those with isolated diastolic hypertension among those who were untreated increased from 11.2 to 45.1.
CONCLUSIONS: The findings of this prospective study suggest that antihypertensive treatment can alter the predictive strength of PP and other blood pressure measures.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16109316     DOI: 10.1016/j.amjhyper.2005.03.735

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  5 in total

1.  Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT).

Authors:  S Theilade; B Claggett; T W Hansen; H Skali; E F Lewis; S D Solomon; H-H Parving; M Pfeffer; J J McMurray; P Rossing
Journal:  J Hum Hypertens       Date:  2015-03-26       Impact factor: 3.012

Review 2.  Risk Associated with Pulse Pressure on Out-of-Office Blood Pressure Measurement.

Authors:  Yu-Mei Gu; Lucas S Aparicio; Yan-Ping Liu; Kei Asayama; Tine W Hansen; Teemu J Niiranen; José Boggia; Lutgarde Thijs; Jan A Staessen
Journal:  Pulse (Basel)       Date:  2014-11-21

Review 3.  Blood pressure components in clinical hypertension.

Authors:  Michel E Safar; Harold Smulyan
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-09       Impact factor: 3.738

4.  Increase of metabolic syndrome score is an independent determinant of increasing pulse pressure.

Authors:  Jae-Youn Moon; Sungha Park; Chul Min Ahn; Jung Rae Cho; Chan Mi Park; Young-Guk Ko; Donghoon Choi; Myung Ho Jeong; Yangsoo Jang; Namsik Chung
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

5.  Outcome-driven thresholds for ambulatory pulse pressure in 9938 participants recruited from 11 populations.

Authors:  Yu-Mei Gu; Lutgarde Thijs; Yan Li; Kei Asayama; José Boggia; Tine W Hansen; Yan-Ping Liu; Takayoshi Ohkubo; Kristina Björklund-Bodegård; Jørgen Jeppesen; Eamon Dolan; Christian Torp-Pedersen; Tatiana Kuznetsova; Katarzyna Stolarz-Skrzypek; Valérie Tikhonoff; Sofia Malyutina; Edoardo Casiglia; Yuri Nikitin; Lars Lind; Edgardo Sandoya; Kalina Kawecka-Jaszcz; Yutaka Imai; Luis J Mena; Jiguang Wang; Eoin O'Brien; Peter Verhamme; Jan Filipovsky; Gladys E Maestre; Jan A Staessen
Journal:  Hypertension       Date:  2013-12-09       Impact factor: 10.190

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.